Jump to content

ARCT-021

From Wikipedia, the free encyclopedia
(Redirected from Draft:ARCT-021)

This article is about the American vaccine. For other uses, see Arcturus COVID-19 vaccine.
ARCT-021
Vaccine description
TargetSARS-CoV-2
Vaccine typesa-mRNA
Clinical data
Other namesLUNAR-COV19
Routes of
administration		Intramuscular
Identifiers
CAS Number
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
virus icon COVID-19 portal

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

Medical uses

[edit]

It requires the intramuscular injection with a single dose.[2]

Pharmacology

[edit]

ARCT-021 is an self-amplifying mRNA vaccine.[3][4]

History

[edit]

Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.[5] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.[6]

Clinical trials

[edit]

LUNAR-COV19 clinical trials in humans began in July 2020.[7] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.[8]

Economics

[edit]

Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.[9][10]

References

[edit]
  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ "Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data". Businesswire. 10 May 2021. Retrieved 9 September 2021.
  3. ^ Low JG, de Alwis R, Chen S, Kalimuddin S, Leong YS, Mah TK, Yuen N, Tan HC, Zhang SL, Sim JX, Chan YF, Syenina A, Yee JX, Ong EZ, Sekulovich R, Sullivan BB, Lindert K, Sullivan SM, Chivukula P, Hughes SG, Ooi EE (December 2022). "A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine". npj Vaccines. 7 (1): 161. doi:10.1038/s41541-022-00590-x. PMC 9745278. PMID 36513697.
  4. ^ "Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". Globe Newswire. 11 August 2020.
  5. ^ Teo J (15 April 2020). "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. Retrieved 27 April 2020.
  6. ^ Stanton D (6 May 2020). "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. Retrieved 8 May 2020.
  7. ^ Clinical trial number NCT04480957 for "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects" at ClinicalTrials.gov
  8. ^ "Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. 4 January 2021. Retrieved 17 January 2021.
  9. ^ Anwar N (26 November 2020). "Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021". CNBC. Retrieved 18 March 2021.
  10. ^ Cheok M, Mookerjee I (5 August 2020). "Singapore Will Get First Claim to Any Successful Arcturus Vaccine". Bloomberg. Retrieved 18 March 2021.
[edit]
Scholia has a profile for Lunar-COV19 (Q98713328).
Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ARCT-021&oldid=1252707927"